Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program.

Abstract excerpt

BACKGROUND/OBJECTIVES: Elenbecestat, an oral BACE-1 inhibitor that has been shown to reduce Aβ levels in cerebrospinal fluid, was investigated in two global phase 3 studies in early AD. Here we report on differences observed in characteristics of APOE ε4 and amyloid positive subjects in the large screening cohort. DESIGN: Screening was performed in 5 sequential tiers over a maximum of 80 days, as part of placebo...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amyloid
• Share to Amyloid beta-Peptides
• Share to Aniline Compounds